Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 2/20 | 0.39 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.37 |
| ▸ | ALB | P02768 | 2/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23323338 | 1.00 | EPHX2 (0.40) | EPHX2SMN1; SMN2NAAAITGB1ITGA4 | |
| SCHEMBL23552243 | 1.00 | EPHX2 (0.40) | EPHX2SMN1; SMN2NAAAITGB1ITGA4 | |
| SCHEMBL23323337 | 1.00 | EPHX2 (0.40) | EPHX2SMN1; SMN2NAAAITGB1ITGA4 | |
| SCHEMBL18811277 | 0.84 | FOLH1 (0.40) | SMN1; SMN2ITGB1ITGA4ALBFOLH1 | |
| SCHEMBL20999267 | 0.81 | ITGB1 (0.36) | SMN1; SMN2NAAAITGB1ITGA4EPHX1 | |
| SCHEMBL23566949 | 0.79 | NAAA (0.49) | EPHX2SMN1; SMN2NAAAEPHX1 | |
| SCHEMBL21261925 | 0.76 | ALDH1A1 (0.49) | EPHX2SMN1; SMN2 | |
| SCHEMBL18811817 | 0.76 | ALDH1A1 (0.49) | EPHX2SMN1; SMN2 | |
| SCHEMBL18814368 | 0.76 | ALDH1A1 (0.49) | EPHX2SMN1; SMN2 | |
| SCHEMBL25619253 | 0.71 | SMN1; SMN2 (0.39) | EPHX2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024267-A1 | METHODS OF ADMINISTERING GLUTATHIONE PRECURSORS | NEURONASAL INC (US) | 2024-01-25 | — | — | US | disclosed |
| WO-2021127541-A1 | METHODS OF TREATING BRAIN DISORDERS | Neuronasal, Inc. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024267-A1 | METHODS OF ADMINISTERING GLUTATHIONE PRECURSORS | GSR, GSS, GSTA2 | EPHX2 655/4885SMN1; SMN2 712/4885NAAA 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.